English | 简体中文 | 繁體中文 | 한국어
Share:
Bavarian Nordic to Host First Quarter 2018 Results Conference Call

COPENHAGEN, Denmark - May 16, 2018 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) will announce its 2018 first quarter results on Thursday, May 24, 2018.

The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) on the same day to present the interim results followed by a Q&A session. A live and replay version of the call and relevant slides will be available at http://bit.ly/2KzQlN2.

To join the Q&A session dial one of the following numbers and state the participant code 8332812: Denmark: +45 35 15 81 21, UK: +44 (0) 330 336 9411, USA: +1 323-794-2551.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43
U.S.: Seth Lewis, Vice President, Investor Relations & Communications. Phone: +1 978 341 5271

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative and safe therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our IMVAMUNE® non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Registration studies are currently underway in the U.S. In addition to our long-standing collaboration with the U.S. government on the development of IMVAMUNE® and other medical countermeasures, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, in collaboration with the National Cancer Institute, we have developed a portfolio of active cancer immunotherapies, designed to alter the disease course by eliciting a robust and broad anti-cancer immune response while maintaining a favorable risk-benefit profile. Through multiple industry collaborations, we seek to explore the potential synergies of combining our immunotherapies with other immune-modulating agents, e.g. checkpoint inhibitors.

For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire

Copyright © Thomson Reuters 2019. All rights reserved.
Press Releases
Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine  
Jan 18, 2019 07:15 ET
Ethan Allen Announces Earnings Release Date for Fiscal 2019 Second Quarter Results  
Jan 17, 2019 22:30 ET
Ossur Hf : Q4&FY 2018 Results - Conference call Tuesday 5 February at 9:00 CET  
Jan 17, 2019 13:42 ET
REC Silicon - Presentation at the Pareto Securities Power and Renewable Energy Conference 2019  
Jan 17, 2019 13:40 ET
Change in Valmet Oyj's holding of treasury shares  
Jan 17, 2019 13:00 ET
INGREDION TO RELEASE 2018 FOURTH-QUARTER AND YEAR-END FINANCIAL RESULTS AND HOLD CONFERENCE CALL AND WEBCAST ON TUESDAY, FEBRUARY 5, 2019  
Jan 15, 2019 01:59 ET
Eastman Schedules Fourth-Quarter and Full-Year 2018 Financial Results News Release and SEC Form 8-K Filing, Teleconference and Webcast  
Jan 10, 2019 23:29 ET
Particle Sciences strengthens nanomilling offering with new API screening program  
Jan 9, 2019 21:59 ET
Lubrizol Performance Coatings Group Introduces New Blog Page  
Jan 8, 2019 22:29 ET
Verisk Launches Black Box 3  
Jan 8, 2019 21:59 ET
More News >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: